Central Nervous System Pharmacology Practice Questions

Q: What are the possible CNS effects of local anesthetic agents?

All of the options. ***All of the options*** - **All three listed effects are genuine CNS manifestations** of local anesthetic systemic toxicity (LAST). - Local anesthetics produce a **biphasic CNS effect**: initial excitatory symptoms (perioral numbness, seizures) followed by depressive symptoms at higher concentrations. - Since the question asks for "**possible** CNS effects" (not the most severe or primary effect), all listed options are medically accurate answers. **CNS Effects of Local Anesthetics:** **Early/Excitatory Phase:** - *Perioral numbness* - Often the first CNS sign, indicating rising plasma levels; numbness and tingling around the mouth and tongue - *Convulsions/Seizures* - Result from blockade of inhibitory neurons, causing uninhibited excitatory activity; a serious manifestation requiring immediate treatment **Late/Depressive Phase:** - *Depression* - Occurs at very high toxic concentrations; includes CNS depression, loss of consciousness, respiratory depression, and potentially coma - This follows the excitatory phase as local anesthetics depress all neuronal activity at extremely high doses *Convulsions alone* - While convulsions are a serious and characteristic CNS effect, they represent only one possible manifestation, not all possible effects. *Perioral numbness alone* - This is an early warning sign of LAST but not the only CNS effect possible. *Depression alone* - This is a late-stage effect but not the only CNS manifestation possible.

Q: What is the drug of choice for smoking cessation?

Varenicline. ***Varenicline*** - **Varenicline** is a **partial agonist** at the **α4β2 nicotinic acetylcholine receptor**, reducing cravings and withdrawal symptoms while blocking the pleasurable effects of nicotine [1]. - It is often considered the **first-line pharmacological treatment** for smoking cessation due to its superior efficacy compared to other monotherapies. *Acamprosate* - **Acamprosate** is primarily used to maintain **abstinence from alcohol** in patients with alcohol dependence. - Its mechanism involves modulating **glutamatergic activity**, primarily at **NMDA receptors**, which is not directly relevant to nicotine addiction. *Thalidomide* - **Thalidomide** is an **immunomodulatory** and **anti-angiogenic drug** used in conditions like **multiple myeloma** and **leprosy**. - It has no role or approved indication for **smoking cessation**. *Tryptophan* - **Tryptophan** is an **amino acid** that serves as a precursor to **serotonin**, a neurotransmitter involved in mood regulation. - While sometimes explored for mood or sleep issues, it is **not indicated** or effective as a primary treatment for **smoking cessation**.

Q: Which of the following drugs is useful in the prophylaxis of migraine?

Propranolol. ***Propranolol*** - **Propranolol** is a **beta-blocker** commonly used for **migraine prophylaxis** by reducing the frequency and severity of attacks. - It works by modulating **serotonergic pathways** and reducing the body's **fight-or-flight response**, which can be a trigger for migraines. *Sumatriptan* - **Sumatriptan** is a **serotonin (5-HT1B/1D) receptor agonist** used for the **acute treatment** of migraine attacks, not for prophylaxis. - It works by causing **vasoconstriction** of cranial blood vessels and inhibiting the release of **pro-inflammatory neuropeptides**. *Domperidone* - **Domperidone** is a **dopamine antagonist** used as an **antiemetic** to relieve nausea and vomiting, which can be associated with migraine attacks. - It does not have a role in the **prophylactic treatment** of migraine itself. *Ergotamine* - **Ergotamine** is an **ergot alkaloid** used for the **acute treatment** of moderate to severe migraines. - Due to its potential for **vasoconstriction** and **drug-induced headache** (medication overuse headache), it is not recommended for routine prophylaxis.

Q: Which drug is contraindicated in the treatment of absence seizures?

Tiagabine. ***Tiagabine*** - **Tiagabine** is an antiepileptic drug that selectively inhibits the reuptake of **GABA** (gamma-aminobutyric acid) in the brain, thereby increasing GABAergic transmission [1, 2, 3]. This mechanism is primarily effective in **focal seizures** and sometimes in **generalized tonic-clonic seizures** [2, 3]. - While tiagabine is used for other seizure types, it is known to **exacerbate absence seizures**, making it contraindicated in their treatment [1]. This paradoxical effect is thought to be due to its complex influence on thalamocortical networks involved in absence seizure generation [1, 2].*Ethosuximide* - **Ethosuximide** is a first-line agent specifically for **absence seizures**. It acts by blocking **T-type calcium channels** in the thalamic neurons, which are crucial for the generation of the characteristic 3-Hz spike-and-wave discharges of absence seizures. - It is highly effective in reducing or eliminating absence seizures with a favorable side effect profile, making it a preferred choice for this specific seizure type.*Clonazepam* - **Clonazepam** is a **benzodiazepine** that enhances the effect of GABA at GABA-A receptors, leading to increased neuronal inhibition. It is effective in various seizure types, including **absence seizures** and **myoclonic seizures**. - While not a first-line treatment due to its sedative side effects and potential for tolerance, it can be used as an adjunct or alternative when other medications are ineffective or not tolerated.*Valproate* - **Valproate** (valproic acid) is a broad-spectrum antiepileptic drug effective against a wide range of seizure types, including **absence seizures**, myoclonic seizures, and **generalized tonic-clonic seizures**. - Its mechanism of action is multifaceted, involving increased GABA synthesis and decreased degradation, voltage-gated sodium channel blockade, and modulation of T-type calcium channels, making it a highly versatile agent.

Q: In the context of patients with liver failure, how does temazepam compare to diazepam?

Safer for patients with liver failure. ***Safer for patients with liver failure*** - Temazepam is primarily metabolized by **conjugation** (glucuronidation), resulting in inactive metabolites that are readily excreted by the kidneys. - This metabolic pathway is generally less impaired in the presence of **liver dysfunction** compared to oxidative metabolism. *Has a longer duration of action than diazepam* - Temazepam generally has a **shorter half-life** and duration of action compared to diazepam. - Diazepam's prolonged effect is largely due to its **active metabolites** which have long half-lives. *Undergoes extensive hepatic metabolism* - While temazepam does undergo hepatic metabolism, its primary pathway is **conjugation**, which is less reliant on the oxidative enzyme systems that are often compromised in liver failure. - In contrast, diazepam undergoes extensive **oxidative metabolism**, making it more problematic in liver dysfunction. *Has active metabolites that can accumulate in liver failure* - Temazepam's main metabolites are **inactive glucuronides**, which do not accumulate to produce significant pharmacological effects, even in liver failure. - **Diazepam**, however, is metabolized to active compounds like **desmethyldiazepam** and **oxazepam**, which can accumulate and cause prolonged sedation in liver failure.

Q: All of the following are CNS stimulants except?

Benzodiazepines. ***Correct Answer: Benzodiazepines*** - **Benzodiazepines** are the correct answer because they are central nervous system (CNS) **depressants**, NOT stimulants. - They enhance the effect of the neurotransmitter **GABA** at the GABA-A receptor, leading to decreased neuronal excitability. - They cause sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. *Incorrect: Amphetamines* - **Amphetamines** are potent CNS **stimulants** that increase the release of dopamine and norepinephrine, leading to increased alertness, energy, and focus. - They are commonly prescribed for conditions like attention-deficit/hyperactivity disorder (ADHD) and narcolepsy, but also have high potential for abuse. *Incorrect: Cocaine* - **Cocaine** is a powerful CNS **stimulant** that blocks the reuptake of dopamine, norepinephrine, and serotonin in the brain, resulting in a rapid onset of euphoria, increased energy, and heightened sensory perception. - Its effects are short-lived, leading to a strong craving for more, and it has significant cardiovascular and neurological risks. *Incorrect: Methylphenidate* - **Methylphenidate** is a CNS **stimulant** structurally similar to amphetamines, primarily used in the treatment of ADHD and narcolepsy. - It works by blocking the reuptake of dopamine and norepinephrine, increasing the concentration of these neurotransmitters in the synaptic cleft, and improving attention and focus.

Q: Modafinil is a drug used in which of the following conditions?

Shift work disorder. ***Shift work disorder*** - **Modafinil** is a **wake-promoting agent** approved by the FDA for improving wakefulness in patients with excessive sleepiness associated with **shift work sleep disorder**. - It helps individuals maintain alertness during atypical work hours, overcoming disruption to their natural circadian rhythm. - **Note:** Modafinil's **primary indication is narcolepsy**, but among the given options, shift work disorder is the correct answer. *Chronic fatigue syndrome* - While fatigue is a primary symptom of **chronic fatigue syndrome**, modafinil is generally **not recommended** as a standard treatment. - Its efficacy in this condition is limited and inconsistent, and management focuses on symptom control and lifestyle adjustments. *Chronic pain syndrome* - **Modafinil has no direct analgesic properties** and is not indicated for **chronic pain syndrome**. - Treatment for chronic pain involves addressing underlying causes with appropriate analgesics or interventional therapies. *Insomnia* - **Modafinil is a wakefulness-promoting agent** and would be **contraindicated in insomnia**, as it would worsen the inability to sleep. - Insomnia is treated with sleep hygiene, cognitive behavioral therapy, or sedative-hypnotics.

Q: Which of the following is used for the patient on antiparkinsonian medication levodopa + carbidopa, but patient showing marked on-off effect?

Selegiline. ***Selegiline*** - **Selegiline** is a **MAO-B inhibitor** that slows the breakdown of dopamine in the brain, thus extending the therapeutic effect of **levodopa** and reducing motor fluctuations including "on-off" phenomena. - It works by inhibiting the enzyme monoamine oxidase type B, which metabolizes dopamine, thereby preserving both endogenous and levodopa-derived dopamine for more sustained dopaminergic stimulation. - **MAO-B inhibitors** are established adjuncts to levodopa therapy for managing motor complications and reducing "off" time. *Bromocriptine* - **Bromocriptine** is a **dopamine agonist** that directly stimulates dopamine receptors (particularly D2 receptors) and has a longer half-life than levodopa, providing more continuous dopaminergic stimulation [1]. - While dopamine agonists are also effective for motor fluctuations, **Selegiline** is often preferred as an initial adjunct due to its better tolerability profile and lower risk of inducing dyskinesias. - Bromocriptine can cause more side effects including **dyskinesias**, **hallucinations**, and **nausea**, particularly in elderly patients [1]. *Amantadine* - **Amantadine** is an **NMDA receptor antagonist** primarily used to treat **levodopa-induced dyskinesia** rather than motor fluctuations. - While it has mild antiparkinsonian effects, it is not the preferred agent for managing "on-off" phenomena specifically. - Its mechanism does not directly prolong levodopa's effect or prevent dopamine breakdown. *Rimonabant* - **Rimonabant** is a **cannabinoid receptor 1 (CB1) antagonist** that was previously marketed for obesity and smoking cessation but was **withdrawn from the market** due to serious psychiatric adverse effects including depression and suicidality. - It has **no role** in the management of **Parkinson's disease** or its motor complications.

Q: Which of the following drug pairs is correctly matched?

Peripheral decarboxylase inhibitor - Benserazide. ***Peripheral decarboxylase inhibitor - Benserazide*** - **Benserazide** is a **peripheral decarboxylase inhibitor** that is commonly co-administered with **levodopa** to prevent its metabolism in the periphery. - By inhibiting the breakdown of levodopa outside the brain, **more levodopa can cross the blood-brain barrier**, where it is then converted to dopamine. *MAO-A inhibitor - Selegiline* - **Selegiline** is an **MAO-B inhibitor**, not an MAO-A inhibitor. It selectively inhibits the enzyme **monoamine oxidase B**, which is responsible for dopamine breakdown in the brain. - **MAO-A inhibitors** (like moclobemide) are primarily used as antidepressants, as they inhibit the breakdown of serotonin and norepinephrine. *COMT inhibitor - Rasagiline* - **Rasagiline** is an **MAO-B inhibitor**, similar to selegiline, used in the treatment of **Parkinson's disease** to reduce the breakdown of dopamine. - **COMT inhibitors** (like entacapone and tolcapone) block the enzyme **catechol-O-methyltransferase**, another enzyme involved in the peripheral and central metabolism of levodopa and dopamine. *Dopamine agonist - Amantadine* - **Amantadine** is an **antiviral drug** that also has **anti-Parkinsonian effects**, primarily through its influence on dopamine release and reuptake, as well as NMDA receptor antagonism. - While it modulates dopamine, it is not classified as a direct **dopamine agonist**; true dopamine agonists (like pramipexole and ropinirole) directly stimulate dopamine receptors.

Q: Which of the following is true about barbiturates?

Shows GABA facilitatory action. ***Shows GABA facilitatory action*** - Barbiturates enhance the effect of **GABA** (gamma-aminobutyric acid), the primary inhibitory neurotransmitter in the central nervous system, by increasing the **duration** of chloride channel opening. - This facilitatory action leads to **hyperpolarization** of neurons, making them less excitable and resulting in CNS depression. - This is the **primary mechanism** of action of barbiturates at therapeutic doses. *Enhances GABAergic activity by mimicking GABA's effects* - While barbiturates enhance GABAergic activity, they do not **mimic GABA's effects** in the same direct way that full agonists do. - Instead of acting as direct agonists, barbiturates **allosterically modulate** the GABA A receptor, increasing the receptor's affinity for GABA and prolonging the opening time of the associated chloride channel. *Limbic system is most sensitive to the depressive action of barbiturates to CNS* - The **reticular activating system (RAS)** in the brainstem, which plays a crucial role in regulating wakefulness and arousal, is generally considered the most sensitive area to the depressive effects of barbiturates. - While the limbic system is affected, its sensitivity is not uniquely highest compared to other CNS regions like the RAS, which is critical for the sedative and hypnotic effects observed. *Primarily acts by blocking voltage gated Na+ and K+ channels* - This is **incorrect**. The primary mechanism of barbiturates is through **GABA A receptor modulation**, not by blocking voltage-gated ion channels. - While barbiturates can have non-specific membrane effects on voltage-gated channels at very high (toxic) concentrations, this is not their primary or therapeutic mechanism of action.

Question 1

What are the possible CNS effects of local anesthetic agents?

Accepted Answer

All of the options

Answer

Convulsions

Answer

Perioral numbness

Answer

Depression

Question 2

What is the drug of choice for smoking cessation?

Accepted Answer

Varenicline

Answer

Acamprosate

Answer

Thalidomide

Answer

Tryptophan

Question 3

Which of the following drugs is useful in the prophylaxis of migraine?

Accepted Answer

Propranolol

Answer

Sumatriptan

Answer

Domperidone

Answer

Ergotamine

Question 4

Which drug is contraindicated in the treatment of absence seizures?

Accepted Answer

Tiagabine

Answer

Clonazepam

Answer

Ethosuximide

Answer

Valproate

Question 5

In the context of patients with liver failure, how does temazepam compare to diazepam?

Accepted Answer

Safer for patients with liver failure

Answer

Has a longer duration of action than diazepam

Answer

Undergoes extensive hepatic metabolism

Answer

Has active metabolites that can accumulate in liver failure

Question 6

All of the following are CNS stimulants except?

Accepted Answer

Benzodiazepines

Answer

Cocaine

Answer

Methylphenidate

Answer

Amphetamines

Question 7

Modafinil is a drug used in which of the following conditions?

Accepted Answer

Shift work disorder

Answer

Chronic fatigue syndrome

Answer

Chronic pain syndrome

Answer

Insomnia

Question 8

Which of the following is used for the patient on antiparkinsonian medication levodopa + carbidopa, but patient showing marked on-off effect?

Accepted Answer

Selegiline

Answer

Bromocriptine

Answer

Amantadine

Answer

Rimonabant

Question 9

Which of the following drug pairs is correctly matched?

Accepted Answer

Peripheral decarboxylase inhibitor - Benserazide

Answer

Dopamine agonist - Amantadine

Answer

COMT inhibitor - Rasagiline

Answer

MAO-A inhibitor - Selegiline

Question 10

Which of the following is true about barbiturates?

Accepted Answer

Shows GABA facilitatory action

Answer

Limbic system is most sensitive to the depressive action of barbiturates to CNS

Answer

Enhances GABAergic activity by mimicking GABA's effects

Answer

Primarily acts by blocking voltage gated Na+ and K+ channels

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?